E-7820;CS-2701;ER 68203-00;E 7820; E-7820;E7820, 10 mM in DMSO;ER68203-00;E7820;E-7820;E 7820;289483-69-8;3-Cyano-N-(3-cyano-4-methyl-7-indolyl)benzenesulfonamide;3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide;N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide;Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-
E7820 is a sulfonamide derivative and an angiogenesis inhibitor that inhibits bFGF- and VEGF-stimulated human umbilical vein endothelial cell (HUVEC) proliferation (IC50s = 0.1 and 0.081 μg/ml, respectively). It inhibits bFGF- and VEGF-stimulated tube formation of HUVECs in a concentration-dependent manner (IC50s = 0.2 and 0.24 μg/ml, respectively). E7820 selectively decreases the surface expression and mRNA levels of integrin α2 over CD31 and VE-cadherin in HUVECs. In vivo, E7820 (200 and 400 mg/kg) reduces tumor growth and inhibits angiogenesis in a WiDr colorectal cancer mouse xenograft model. It also reduces tumor weight in a panel of seven human colon, breast, pancreas, and kidney cancer mouse xenograft models, completely inhibits tumor growth in KP-1 pancreatic and LoVo colon cancer mouse xenograft models, and inhibits tumor growth in KP-1 and COLO 320DM mouse orthotopic transplantation models.
